Lisinopril and Tadalafil Interaction: What Women Need to Know

What Is the Interaction Between Lisinopril and Tadalafil?

The core problem is additive blood pressure lowering. Lisinopril, an ACE inhibitor, dilates blood vessels by blocking angiotensin II production. Tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor, dilates blood vessels by preventing the breakdown of cyclic GMP, which relaxes vascular smooth muscle. When you take both, two separate vasodilatory mechanisms stack on top of each other, and your blood pressure can drop further than either drug would cause alone.

This is a pharmacodynamic (PD) interaction, not a pharmacokinetic one. Neither drug substantially alters the metabolism of the other. Lisinopril is not metabolized by cytochrome P450 enzymes and is excreted unchanged by the kidneys. Tadalafil is metabolized primarily by CYP3A4, so no CYP-based drug-drug interaction exists between the two. The risk is purely about blood pressure physiology.

How Large Is the Blood Pressure Drop?

Clinical data on this specific pair in women is limited, but PDE5 inhibitor interaction studies with antihypertensives provide useful numbers. A crossover study found that tadalafil 10 mg reduced mean standing systolic blood pressure by approximately 8 mmHg when combined with antihypertensive agents including ACE inhibitors, compared to antihypertensive alone. Individual responses vary widely, and women with volume depletion (from diuretics, heat, or low intake) or autonomic instability (common in perimenopause) may see larger drops.

Severity Classification

Major DDI databases including Drugs.com and Lexicomp classify this combination as a moderate interaction, meaning it warrants clinical attention and monitoring but is not an absolute contraindication. The FDA tadalafil prescribing information explicitly lists antihypertensives, including ACE inhibitors, as agents that can produce additive hypotension and recommends counseling patients accordingly.

Why Women Take Each of These Drugs

Lisinopril in Women

Lisinopril is one of the most prescribed drugs across all sexes, but it has specific roles in women's health beyond generic hypertension control.

Hypertension across the lifespan. Blood pressure patterns differ by sex. Women tend to have lower blood pressure than men during reproductive years, but this gap narrows and then reverses after menopause. Post-menopausal women have higher rates of hypertension than age-matched men, driven by loss of estrogen's vasodilatory and natriuretic effects. Lisinopril is a first-line agent in this context.

PCOS and kidney protection. Women with polycystic ovary syndrome (PCOS) who develop insulin resistance and hypertension may be prescribed lisinopril for both blood pressure control and early renal protection, given their elevated long-term risk of diabetic kidney disease.

Heart failure with reduced ejection fraction. Lisinopril remains a guideline-directed therapy in heart failure. Women with heart failure more often have preserved ejection fraction (HFpEF), but reduced EF (HFrEF) does occur, particularly in peripartum cardiomyopathy survivors.

Diabetic nephropathy. Women with type 1 or type 2 diabetes and proteinuria are candidates for ACE inhibitor therapy to slow kidney disease progression, consistent with ADA Standards of Care guidelines.

Tadalafil in Women

This is where the female-specific framing matters most. Tadalafil is not just a drug for erectile dysfunction. Several approved and off-label indications apply directly to women.

Pulmonary arterial hypertension (PAH). PAH disproportionately affects women, with a female-to-male ratio of approximately 2:1 to 4:1. Tadalafil 40 mg once daily is FDA-approved for PAH under the brand name Adcirca, and clinical trial data from the PHIRST trial (N=405) showed that tadalafil 40 mg improved 6-minute walk distance by a median of 33 meters versus placebo in PAH patients, many of whom were women. A woman on both lisinopril for systemic hypertension and tadalafil for PAH is a realistic clinical scenario.

Raynaud phenomenon. Women develop Raynaud phenomenon at much higher rates than men, particularly in the setting of connective tissue disease such as systemic sclerosis. Tadalafil is used off-label to reduce digital vasospasm frequency. Doses in Raynaud range from 20 to 40 mg daily.

Female sexual dysfunction. Tadalafil has been studied off-label for hypoactive sexual desire disorder (HSDD) and arousal disorder in women, though evidence in women remains thin and no FDA approval exists for this indication. The honest caveat: most PDE5 inhibitor sexual dysfunction trials enrolled men, and female data is largely extrapolated or from small heterogeneous studies.

The Mechanism in Depth

Understanding the physiology helps you and your prescriber make a better decision.

ACE Inhibition Pathway

Lisinopril blocks the conversion of angiotensin I to angiotensin II. Angiotensin II is a potent vasoconstrictor. Without it, peripheral vascular resistance falls, and blood pressure drops. Lisinopril also prevents bradykinin degradation, which contributes additional vasodilation (and the well-known ACE inhibitor cough, more common in women than men at roughly a 2-fold higher incidence).

PDE5 Inhibition Pathway

Tadalafil blocks PDE5, the enzyme that degrades cyclic guanosine monophosphate (cGMP) in vascular smooth muscle. Higher cGMP levels cause smooth muscle relaxation and vasodilation. This mechanism is active in pulmonary vasculature, systemic vasculature, and the genital tract. The systemic vasodilatory effect is the source of the interaction with lisinopril.

Why the Pathways Converge

Both drugs ultimately increase blood vessel diameter through different molecular entry points. The combined effect on systemic vascular resistance is not simply additive in a predictable linear sense. It depends on your baseline blood pressure, your volume status, your renal function (which affects lisinopril clearance), and whether tadalafil is dosed daily (steady-state) versus as-needed. Women on daily tadalafil for PAH have consistent circulating drug levels, making the interaction continuous rather than episodic.

Women-Specific Risk Factors That Amplify This Interaction

The following framework describes risk categories specific to women that increase hypotension severity when lisinopril and tadalafil are combined. No single published guideline consolidates these, but each factor is grounded in established physiology.

Perimenopausal autonomic instability. Estrogen withdrawal during perimenopause disrupts autonomic cardiovascular regulation, increasing baroreflex sensitivity variability. Hot flashes themselves cause transient vasodilation. A woman experiencing a hot flash while taking both drugs may experience compounded vasodilation that no trial has specifically measured.

Concurrent diuretic use. Many women on lisinopril for hypertension also take hydrochlorothiazide (HCTZ). Volume depletion from the diuretic reduces the buffer against blood pressure drops from the lisinopril-tadalafil combination. The lisinopril FDA label explicitly flags this risk in patients also receiving diuretics.

Lower body weight. Women on average have lower body weight and lower lean muscle mass than men. Drug exposure per kilogram is higher at equivalent doses, a factor not always adjusted for in prescribing.

Orthostatic hypotension risk. Orthostatic hypotension is more prevalent in older women, particularly those with diabetes or autonomic neuropathy. Adding two vasodilators to this picture raises fall and syncope risk in a meaningful way.

Renal function and lisinopril clearance. Lisinopril is excreted unchanged by the kidneys. Women with CKD, which can occur in PCOS-related diabetes or autoimmune disease common in women, accumulate higher lisinopril drug levels. Dose adjustments for lisinopril based on GFR are specified in the FDA label: reduce starting dose to 2.5 mg/day when eGFR is <30 mL/min/1.73 m².

Pregnancy and Lactation: Both Drugs Are Contraindicated in Pregnancy

This section is required reading if you are pregnant, planning pregnancy, or not using reliable contraception.

Lisinopril in Pregnancy

Lisinopril is teratogenic and fetotoxic. The FDA classifies ACE inhibitors as Category D in the second and third trimester and warns of fetal renal tubular dysplasia, neonatal renal failure, oligohydramnios, skull hypoplasia, pulmonary hypoplasia, limb contractures, and death. First-trimester exposure data are more equivocal, but ACOG recommends discontinuing ACE inhibitors as soon as pregnancy is confirmed and ideally before conception. If you are of reproductive age and taking lisinopril, you need a plan for what happens if you become pregnant. A prescriber should discuss this with you at the first visit.

Lisinopril does pass into breast milk in small amounts. The FDA label does not recommend breastfeeding while taking lisinopril due to potential neonatal kidney effects. Alternative antihypertensives considered compatible with lactation include nifedipine and labetalol.

Tadalafil in Pregnancy

Human pregnancy data for tadalafil is very limited. Animal reproduction studies showed fetal harm at high doses. The Adcirca (PAH) label states that tadalafil should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Given that PAH itself carries significant maternal mortality risk in pregnancy, the calculus is different for a woman with PAH than for a woman taking tadalafil off-label for Raynaud. That decision requires specialist input.

Tadalafil lactation data is absent. Until safety is established, breastfeeding while taking tadalafil is not recommended.

Contraception Requirement

If you take lisinopril and you might become pregnant, you need effective contraception. Hormonal contraception (combined oral contraceptives) can raise blood pressure slightly, which is a consideration when you are already managing hypertension. Your prescriber may prefer progestin-only methods, intrauterine devices (IUDs), or barrier methods, depending on your full clinical picture.

Who This Combination Is Appropriate For and Who Should Avoid It

Appropriate Candidates

A woman with PAH and co-existing systemic hypertension may need both tadalafil and lisinopril. In this setting, the drugs are prescribed together under specialist supervision, starting with conservative doses and monitoring blood pressure at each position change. Gradual titration, education about hypotension symptoms, and avoidance of additional vasodilatory triggers (alcohol, heat, other antihypertensives) make the combination manageable.

A woman with Raynaud and mild controlled hypertension on a low dose of lisinopril (5-10 mg/day) taking occasional low-dose tadalafil (5 mg) may tolerate the combination without incident, particularly if her baseline blood pressure is not at the lower end of normal.

Who Should Be Cautious or Avoid the Combination

Women with any of the following should discuss alternatives with their prescriber before combining these drugs:

• Baseline systolic blood pressure <110 mmHg
• Concurrent diuretic therapy and evidence of volume depletion
• Symptomatic orthostatic hypotension already documented
• History of syncope or presyncope
• Advanced CKD (eGFR <30) causing lisinopril accumulation
• Age over 65 with fall risk

The combination is not appropriate without close monitoring in these scenarios.

Monitoring and Dose Considerations

Blood Pressure Monitoring Protocol

If your provider decides the combination is appropriate, a practical monitoring plan includes:

• Check sitting and standing blood pressure before starting tadalafil
• Recheck at one week and again at one month after any dose change
• Keep a symptom log: note dizziness, lightheadedness, or near-fainting episodes, particularly in the first hour after tadalafil dosing
• For daily-dosed tadalafil (5 mg or 40 mg), the blood pressure effect is continuous, not episodic

Lisinopril Dose Range

Lisinopril is available in doses from 2.5 mg to 40 mg daily. For hypertension, the standard starting dose is 10 mg once daily, with titration to a usual maintenance dose of 20-40 mg/day. If you are starting tadalafil while already on lisinopril, your provider may consider a temporary dose reduction of lisinopril while your body adjusts.

Tadalafil Dose Range

For PAH, the approved dose is 40 mg once daily. For sexual dysfunction or Raynaud (off-label), doses range from 5 to 20 mg. The hypotension risk scales with the tadalafil dose.

Renal Function and Dose Adjustment

Because lisinopril is renally excreted, women with eGFR between 10 and 30 mL/min/1.73 m² should start at 2.5 mg/day. Tadalafil also requires dose adjustment in severe renal impairment; the Adcirca label recommends avoiding 40 mg once daily in patients with eGFR <31 mL/min/1.73 m² not on hemodialysis.

What to Do If You Feel Dizzy or Faint

Hypotension from this combination is more likely in the first few hours after a tadalafil dose, especially on the first day of use. If you experience sudden dizziness or feel faint:

• Sit or lie down immediately to prevent a fall
• Raise your legs if possible
• Drink water unless your provider has fluid-restricted you
• Check your blood pressure if you have a home monitor
• Contact your prescriber the same day if symptoms are new or severe
• Call emergency services if you lose consciousness or cannot stand

Do not drive or operate machinery if you feel light-headed after taking tadalafil with lisinopril until you know how the combination affects you.

The Evidence Gap for Women: Honest Disclosure

Most PDE5 inhibitor cardiovascular interaction studies enrolled predominantly male participants. The PHIRST trial for tadalafil in PAH included a majority of women (reflecting PAH epidemiology), making it one of the better female-represented datasets for tadalafil cardiovascular effects. But the specific lisinopril-tadalafil blood pressure interaction has not been studied in a female-only or female-majority cohort.

Sex differences in ACE inhibitor pharmacology are real. Women may have higher bradykinin levels at equivalent lisinopril doses compared to men, contributing to the higher cough rate. Whether this translates to greater vasodilatory response per milligram of lisinopril is plausible but not directly measured in published trials. Prescribers are currently extrapolating from male-majority antihypertensive data, and women should know this.

A 2020 analysis in the Journal of the American Heart Association found that women were significantly underrepresented in cardiovascular drug interaction studies, with many trials enrolling fewer than 30% female participants. This is the honest limitation of the current evidence base.

Lisinopril Drug Interactions Beyond Tadalafil: A Women's-Health Snapshot

Lisinopril interacts with several other drug classes women commonly take:

NSAIDs. Ibuprofen and naproxen, commonly used for menstrual pain and arthritis, blunt the antihypertensive effect of lisinopril and increase the risk of acute kidney injury. The interaction is clinically significant even with short-term NSAID use.

Potassium-sparing diuretics and potassium supplements. Spironolactone, used in women for PCOS, acne, and heart failure, combined with lisinopril raises hyperkalemia risk. Regular potassium and creatinine monitoring is needed.

Lithium. Women with bipolar disorder taking lithium may experience lithium toxicity if lisinopril is added, because ACE inhibitors reduce renal lithium excretion.

Combined hormonal contraceptives. These can raise blood pressure, partially offsetting lisinopril's effect. This does not prevent prescribing CHCs but does mean blood pressure should be rechecked 6-8 weeks after starting or changing hormonal contraception in a woman on lisinopril.